SANA Stock Overview
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Sana Biotechnology, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.50 |
| 52 Week High | US$12.00 |
| 52 Week Low | US$2.75 |
| Beta | 1.61 |
| 1 Month Change | -10.15% |
| 3 Month Change | 55.39% |
| 1 Year Change | 63.78% |
| 3 Year Change | -63.78% |
| 5 Year Change | n/a |
| Change since IPO | -75.78% |
Recent News & Updates
Recent updates
Sana Biotechnology: Now In Overbought Territory
Mar 17Sana Biotechnology's One-And-Done Solution For Diabetes Impresses In NHP Model (Rating Upgrade)
Jan 11Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?
Dec 30
Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation
Sep 14Will Sana Biotechnology (NASDAQ:SANA) Spend Its Cash Wisely?
May 26We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate
Dec 19Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation
Sep 03Sana Biotechnology A Buy For Potential Cancer Therapies
Jun 27Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?
May 16Sana Biotechnology: Exciting Preclinical Science
Feb 12Is Sana Biotechnology, Inc. (NASDAQ:SANA) Trading At A 38% Discount?
Oct 13Sana Biotechnology: Hypoimmune Cell Therapies
Jul 01Sana Biotechnology reports Q1 results
May 05Shareholder Returns
| SANA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 10.0% | 0.4% | 1.0% |
| 1Y | 63.8% | 0.9% | 21.9% |
Return vs Industry: SANA exceeded the US Biotechs industry which returned 0.7% over the past year.
Return vs Market: SANA exceeded the US Market which returned 24.9% over the past year.
Price Volatility
| SANA volatility | |
|---|---|
| SANA Average Weekly Movement | 13.6% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SANA's share price has been volatile over the past 3 months.
Volatility Over Time: SANA's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 328 | Steve Harr | www.sana.com |
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company’s product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin’s lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others.
Sana Biotechnology, Inc. Fundamentals Summary
| SANA fundamental statistics | |
|---|---|
| Market cap | US$1.87b |
| Earnings (TTM) | -US$283.25m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-6.6x
P/E RatioIs SANA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SANA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$283.26m |
| Earnings | -US$283.25m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.28 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did SANA perform over the long term?
See historical performance and comparison